Brief: Sab Biotherapeutics Reports NIH Is Discontinuing Phase 3 Activ-2 Trial Assessing Sab-185

SAB Biotherapeutics

02/03/2022 12:31

March 2 (Reuters) - SAB Biotherapeutics Inc  SABS.O :
    * SAB BIOTHERAPEUTICS REPORTS NIH IS DISCONTINUING PHASE 3
ACTIV-2
TRIAL ASSESSING SAB-185 FOR TREATMENT OF COVID-19 DUE TO
DECLINING COVID HOSPITALIZATIONS
    * SAB BIOTHERAPEUTICS INC - EVALUATING FUTURE CLINICAL PLANS
FOR
SAB-185
    * SAB BIOTHERAPEUTICS INC - NIH IS CLOSING ENROLLMENT IN ITS
ACTIV-2 TRIAL
    * SAB BIOTHERAPEUTICS - LOW OMICRON-RELATED COVID-19
HOSPITALIZATION, DEATH RATES IN STUDY HAVE MADE CURRENT STUDY
DESIGN STATISTICALLY UNWORKABLE
    * SAB BIOTHERAPEUTICS INC - DSMB RECOMMENDED THAT STUDY BE
STOPPED
FOR REASONS OF "OPERATIONAL FUTILITY"
    * SAB BIOTHERAPEUTICS-EVALUATING FUTURE SAB-185 CLINICAL
PLANS
INCLUDING TARGETED APPLICATIONS SUCH AS PROPHYLAXIS, TREATMENT
IN HIGH-RISK PATIENT GROUPS

Source text for Eikon:  ID:nGNX7Vkk35 
Further company coverage:  SABS.O 

 ((reuters.briefs@thomsonreuters.com;))